Yifan Pharmaceutical’s unit Evive Biotech wants to take on Amgen in the US market for drugs to help fight post-chemotherapy infection risks. Photo: Shutterstock Images Yifan Pharmaceutical’s unit Evive Biotech wants to take on Amgen in the US market for drugs to help fight post-chemotherapy infection risks. Photo: Shutterstock Images
Yifan Pharmaceutical’s unit Evive Biotech wants to take on Amgen in the US market for drugs to help fight post-chemotherapy infection risks. Photo: Shutterstock Images

Yifan Pharma’s unit, eyeing US$5.5 billion post-chemotherapy treatment market dominated by Amgen, considers IPO in 2021

  • Evive’s F-627 candidate has shown promising results after several phase three clinical trials, CEO Liu Jubo says
  • Amgen’s second best-seller Neulasta, whose patent expired five years ago, generated US$3.2 billion of sales in 2019

Topic |   Pharmaceuticals
Yifan Pharmaceutical’s unit Evive Biotech wants to take on Amgen in the US market for drugs to help fight post-chemotherapy infection risks. Photo: Shutterstock Images Yifan Pharmaceutical’s unit Evive Biotech wants to take on Amgen in the US market for drugs to help fight post-chemotherapy infection risks. Photo: Shutterstock Images
Yifan Pharmaceutical’s unit Evive Biotech wants to take on Amgen in the US market for drugs to help fight post-chemotherapy infection risks. Photo: Shutterstock Images
READ FULL ARTICLE